Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Update from December 13, 2023: The U.S. Supreme Court agreed to take up the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration case. Oral arguments are expected in 2024. Currently medication abortion using mifepristone and misoprostol remains available in Illinois.

Update from August 16, 2023: The U.S. Court of Appeals for the Fifth Circuit issued its decision in the appeal of the trial court’s decision attempting to remove mifepristone from the market. The Fifth Circuit disagreed with the lower court that the FDA’s approval of mifepristone in 2000 could be challenged; however, the appeals court ruled that the anti-abortion advocates’ challenges to the FDA’s decision to update the mifepristone label in 2016 and its 2019 decision to remove the in-clinic dispensing requirement were likely to succeed. Because of the Supreme Court’s April 21, 2023, order, the appeals court decision has no immediate effect, and mifepristone remains legally available in Illinois.

Update from April 21, 2023: The U.S. Supreme Court blocked the lower court decision attempting to remove mifepristone from the market. This means mifepristone remains legally available until after the Supreme Court resolves any appeals.

Update from April 13, 2023: Medication abortion is available in Illinois despite an anti-science decision in Texas. Anti-abortion operatives challenged the FDA’s more than two-decades-old approval of mifepristone, a medication used in combination with misoprostol for medication abortion. On April 7, a federal judge in Texas paused the FDA’s approval of the drug, essentially meaning that the 2000 FDA approval never happened. Minutes later, a federal judge in Washington State ordered the FDA to maintain its approval of mifepristone. Illinois is one of the 17 states (plus DC) covered by the Washington decision that ordered the FDA to not change its approval of mifepristone.

Reproductive Health Services of Planned Parenthood of the St. Louis Region will continue to provide medication abortion using mifepristone and misoprostol in Fairview Heights, Illinois. Patients can make an appointment by calling 618-277-6668.

Overturning Roe v. Wade wasn’t enough for anti-abortion groups. Now — they’re trying to use the court to impede access to sexual and reproductive health care nationwide.

Less than five months after the constitutional right to abortion ended, a group of anti-abortion activists and organizations sued the U.S. Food and Drug Administration (FDA) over its 23 year-old approval of mifepristone, one of two medications most commonly used in medication abortion in the United States. The case, Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al, was deliberately filed in the Amarillo division of the Northern District of Texas — a division with just one Trump-appointed judge who worked for anti-abortion organization. The Alliance for Hippocratic Medicine is one of many sham organizations that have actively worked to undermine sexual and reproductive health care including involvement in Dobbs v. Jackson Women’s Health Organization,the case that overturned Roe v. Wade.

This case has national implications that impact all people seeking abortion care. Any additional restrictions or judicial overreach related to abortion access will worsen the public health crisis in a post-Roe reality..

Medication abortion allows people to manage their abortions on their own terms, expands access to abortion care, and reduces abortion stigma. As more states ban or severely restrict abortion, it’s more important than ever for people to have more options to access care in critical access states.

Mifepristone is a proven safe and effective method of abortion. According to Advancing New Standards in Reproductive Health, medication abortion has a safety record of 99 percent. In addition to being used for terminating a pregnancy, mifepristone is used for miscarriage management and diabetes treatments.

Public support for medication abortion is clear. A February 2023 Ipsos poll shows the overwhelming majority  of people believe medication abortion should remain legal. 

Ideological operatives should have no place in the FDA’s thorough and stringent approval process. The devastating implications of this case go beyond abortion access. This case threatens the FDA’s authority over medication approval and could have far-reaching consequences for patients’ access to other FDA-approved medications.

To understand the baseless claims and truly unprecedented nature of the case, the Washington Post breaks it down. 

  • “Legal experts said that such a ruling, if upheld, could lead to a highly politicized regulatory environment, with approvals for controversial treatments facing court challenges and being thrust into the middle of culture wars. Coronavirus vaccines or hormone treatments for transgender people, they said, could be endangered by judges with no scientific background.”
  • “Critics say the legal theories in the lawsuit are specious, but they acknowledge that Kacsmaryk’s ruling could sow confusion over FDA regulations, weakening an agency at a time when scientific and medical expertise are under attack, possibly inviting lawsuits over any number of previously approved medications.”
  • “The FDA is virtually never reversed by a court on scientific decisions because courts invariably recognize that they don’t have the expertise to make scientific decisions,” said Scott Lassman, a D.C. attorney who specializes in FDA regulatory issues. “And it is even more rare — I’d say unheard of — for this type of scientific challenge to be made in court 20 years after FDA’s decision.”


According to policy experts, possible outcomes for the case include:

  • “Kacsmaryk could determine that the agency did not apply a lawful review process for its initial approval of mifepristone, which “would be unprecedented for a Court to rule that the FDA did not properly approve a drug,” Kaiser Family Foundation researchers wrote.” 
  • “Another option: a more limited ruling that would get rid of prior rules that eliminated the in-person dispensing requirement and allowed for telehealth abortions.” 
  • “He could toss the lawsuit, embracing the Justice Department argument that the groups don’t have standing to sue.”

Planned Parenthood of the St. Louis Region and Southwest Missouri will always be here for patients. Learn more about abortion options at our health center in Fairview Heights, Illinois. 

Click below to learn more. 


What’s MO got to do with the FDA Mifepristone case?

Tags: Abortion, Roe v. Wade, reproductive health, AbortionProviders, mifepristone, MIFE

Explore more on


This website uses cookies

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.



We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.



We use qualitative data, including session replay, to learn about your user experience and improve our products and services.



We use web analytics to help us understand user engagement with our website, trends, and overall reach of our products.